Bristol-Myers Squibb moves cardiac ultrasound agent closer to European market:
This article was originally published in Clinica
Executive Summary
Bristol-Myers Squibb (BMS) has moved a major step closer to gaining European market clearance for its echocardiography contrast agent, Luminity (perflutren 150 microlitres/ml solution). The EU's Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission grant a marketing authorisation for use of the product in patients in whom non-contrast echocardiography is suboptimal and who have suspected or established coronary artery disease. The ultrasonic properties of the perflutren-containing lipid microspheres generated after activation of Luminity are very different from those of soft tissue, enhancing blood echogenicity and increasing contrast between blood and the surrounding tissues during echocardiography.